Comet Biotech AS:

The Latest High Throughput Assays


Home    February 25, 2017  English (United States) Español (España)

Comet Biotech AS provides the latest, state-of-the-art, high throughput assays targeted at the chemical industry, cosmetic and pharmaceutical companies, regulatory bodies, the REACH programme, basic genome research and biomonitoring projects.

Toxicity testing
Our tests for genotoxicity, cytotoxicity, mutagenesis, DNA damage and repairare backed by leading researchers in these fields.
Expertise and consulting
The core interest of the company is the comet assay, but we also offer a range of additional assays for genotoxicity and cytotoxicity. 
Read more  
Research Activities
With our background in academic research, we are keen to contribute as an SME to research projects.

Read more 

Education and training
We can offer training courses in the comet assay and other techniques. We also provide a consultancy service, backed up by the leading experts in this field.

Read more 

Latest news
Project with Kraft
The project with Kraft (now known, in Europe, as Mondelez) was successfully completed early last year. Since then, we have been writing up the results for publication; the manuscript is in the final stages of preparation. We hope to give more details of the project, and announce the results, very soon.
Enhanced detection of genotoxic effects with the comet assay

Comet BioTech founders Amaya Azqueta and Andrew Collins, with colleagues, have just published the results of a systematic test of the comet assay in combination with the enzyme FPG.

Whereas the standard comet assay fails to detect (at non-cytotoxic doses) many chemicals known to be carcinogenic or mutagenic, because they do not induce DNA breaks, the addition of a digestion of DNA with  FPG greatly enhances the  assay’s sensitivity, making possible the detection of chemicals such as methylnitrosourea, benzo(a)pyrene and 4-nitroquinoline-1-oxide.

Among the non-genotoxic chemicals tested, there were no ’false positives’. We believe that the modified comet assay can play an important role in screening chemicals for DNA-damaging effects.

See: Enhancing the sensitivity of the comet assay as a genotoxicity test, by combining it with bacterial repair enzyme FPG. Azqueta AArbillaga L

Research on nanoparticles

Comet BioTech founder Maria Dusinska coordinated the European project NanoTEST (Alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics). A collection of papers reporting the findings of this project will be published as a special issue of the journal Nanotoxicology.

Comet BioTech is currently a member of the Nanotechnology Industries Association, NIA, the sector-independent, responsible voice for the industrial nanotechnologies supply chains.

  Copyright 2009 by DotNetNuke Corporation   Terms Of Use  Privacy Statement    Login